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Chest Wall Sarcomas are Accurately Diagnosed by
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Objective: Sarcomas are rare mesenchymal malignancies. Accurate
preoperative diagnosis is a prerequisite in considering investiga-
tional or institutional management algorithms that include neoadju-
vant treatment. We reviewed our experience using core needle
biopsy for chest wall sarcomas.
Methods: A retrospective review of our sarcoma databases revealed
that 40 core needle biopsies and 35 tumor resections were performed
in 34 patients, with chest wall musculoskeletal tumors, referred to
the University of California, Los Angeles from 1991 to 2010.
Primary, metastatic, or recurrent sarcomas involving the sternum,
ribs, and soft tissues of the chest wall were evaluated for (1)
adequacy of tissue from image-guided core needle biopsies and (2)
accuracy in determining malignancy, histological subtype, and sar-
coma grade.
Results: Twenty-eight of the 40 needle biopsy samples (70%) were
adequate for histopathological analysis. Forty-two percent of non-
diagnostic findings occurred due to insufficient tissue, whereas the
remainder had sufficient tissue, but the pathologist was unable to
determine specific histology. Excluding the nondiagnostic samples,
the accuracy in determining malignancy, histological subtype, and
grade in sarcomas was 100, 92, and 87%, respectively. The sensi-
tivity and specificity of determining malignancy and high-grade
sarcomas were 100, 100, 77, and 100%, respectively. There were no
complications from the image-guided biopsies.
Conclusions: We demonstrated that image-guided core needle bi-
opsy when performed and reviewed by experienced radiologists and
musculoskeletal pathologists is a safe and accurate diagnostic tech-
nique for chest wall sarcomas. Core needle biopsy should be
considered in the multidisciplinary approach to chest wall muscu-
loskeletal tumors, especially when induction therapy is considered.
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Sarcomas are a heterogeneous group of uncommon tumorsthat arise from mesenchymal cells, accounting for less
than 1% of adult malignancies.1 Many histological subtypes
have been identified and are broadly divided into soft tissue
or bony types. In the United States, there are approximately
7000 reported cases of soft tissue and 2500 bony sarcomas
per year.2 Approximately 7% of primary sarcomas arise from
the chest wall and account for a significant number of deaths
from malignant tumors.3
Although surgical resection is the established standard
treatment of soft tissue and bony sarcomas, the impact of
chemotherapy and/or radiation on more aggressive tumors
remains unclear. Histology and grade are important factors in
determining the use of these adjuvant modalities. Further-
more, the use of neoadjuvant or preoperative therapy, partic-
ularly in soft tissue sarcomas, is an evolving field of inves-
tigation and remains controversial. An accurate preoperative
diagnosis of sarcoma and grade are prerequisites to investi-
gational or institutional treatment algorithms that apply neo-
adjuvant approaches.
Previously, open surgical biopsies have been consid-
ered the gold standard for diagnosis but have associated
complications, including risks for seroma, infection, wound
dehiscence, and tumor implantation. Additional disadvan-
tages include the time and cost of operating room usage and
inappropriately placed incisions that may compromise defin-
itive resection or cosmesis. Mankin et al.4 reported open
biopsy complication rates of 19.3% that resulted in alteration
of treatment plans in 10.1% of patients. Alternatively, image-
guided core needle biopsies have shown accurate diagnostic
results without the disadvantages of surgical biopsy in the
extremity.5–9 Although there have been many studies that
evaluated the experience of needle biopsies in chest wall
lesions, these studies included all types of malignancies,
particularly carcinomas, as well as benign tumors and ab-
scesses. As such, reports that address the efficacy of core
needle biopsies in chest wall musculoskeletal tumors and
specifically its application in chest wall sarcomas are limited.
This study focuses on our experience with the use of core
needle biopsy in primary, metastatic, and recurrent sarco-
mas involving the sternum, ribs, or soft tissues of the chest
wall and specifically addresses (1) adequacy of tissue
sample obtained by needle biopsy and (2) accuracy in
determining malignancy, histological subtype, and high
grade differentiation.
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PATIENTS AND METHODS
A retrospective review of our prospectively maintained
sarcoma databases revealed that 40 core needle biopsies were
performed in 34 patients, with chest wall musculoskeletal
tumors, referred to the David Geffen School of Medicine at
University of California, Los Angeles between 1991 and
2010. Patient and tumor characteristics were obtained follow-
ing institutional review board approval.
Chest wall tumor was defined as any neoplasm involv-
ing the sternum, clavicle, ribs, or soft tissues overlying the
ribs. The core needle biopsy procedures were performed by
five thoracic or musculoskeletal radiologists, who attend a
weekly, multidisciplinary musculoskeletal (sarcoma) tumor
board at a tertiary referral center that averages more than
1200 new sarcoma cases per year. All biopsies were per-
formed in the outpatient setting using ultrasound or computed
tomography (CT) guidance.
The technique of image-guided core needle biopsies at
University of California, Los Angeles is described. The chest
wall was prepped and draped sterilely before being infiltrated
with 1% lidocaine for local anesthesia. Intravenous sedation
was not required for any patient. Under image guidance, a
large (11 or 17–19-gauge outer cannula) introducer needle
was advanced to the proximal margin of the tumor, and a
smaller (14 or 18–20-gauge cutting needle) core biopsy
system was placed through the introducer needle to obtain the
tissue sample. Soft tissue, lytic bony tumors or bony tumors
with soft tissue extensions were biopsied using an automated
14-gauge cutting needle (Quickcore, Cook, Bloomington,
IN). Variations in technique reflect the individual radiologist
performing the procedure with respect to imaging modality,
needle type, and needle size. High-resolution scans (single
versus multidetector CT) were not required to localize the
tumor or to guide needle entry and trajectory when perform-
ing needle biopsies. The decision of preferred imaging tech-
nique was made by the performing radiologist. In general,
either modality can be used in chest wall tumors, especially
when there is a significant extrathoracic component. In these
situations, the larger needles (11-gauge outer and 14-gauge
inner) were used. CT guidance with smaller needles was
preferred particularly in situations where the chest wall tumor
had a predominant intrathoracic component or in locations
adjacent to the mediastinum. An average of four to six core
samples with a cutting needle was taken from the mass.
Tissue samples for hematoxylin and eosin staining and im-
munohistochemical testing were placed in formalin, and sam-
ples for karyotyping were placed in saline. Pressure was
maintained on the skin entry site to achieve hemostasis.
The pathologic review of the core needle biopsy spec-
imens was performed by one of two designated musculosk-
eletal pathologists, who attend and participate in a multidis-
ciplinary, weekly musculoskeletal (sarcoma) tumor board.
Soft tissue sarcomas were graded using the French Federation
of Cancer Centers Sarcoma Group grading system, and bony
sarcomas were classified as grade 1, 2, or 3 as per convention.
Adequacy of biopsies was defined as samples with
sufficient tissue and cellular architecture allowing the pathol-
ogist to make a histologic diagnosis. Nondiagnostic biopsies
included either samples with insufficient amount of tissue or
samples with sufficient cellularity but inadequate for a defin-
itive pathologic diagnosis. Accuracy was defined as the
ability to correctly determine (1) presence of malignancy, (2)
histological subtype, and (3) sarcoma grade. Sensitivity,
specificity, positive predictive value, and negative predictive
value (NPV) for distinguishing tumor histology and grade
were calculated from only adequate samples based on stan-
dard statistical definitions.
Based on pathologic findings from the core needle
biopsy, patients with high-grade soft tissue and bony sarco-
mas sensitive to chemotherapy and/or radiation were selected
to undergo neoadjuvant therapy. All patients subsequently
underwent surgical extirpation. Most patients required full-
thickness chest wall resection that included ribs. Forty core
needle biopsy pathology findings were analyzed to determine
adequacy of tissue sample obtained and were compared with
the 35 surgically resected specimens to determine accuracy of
diagnosis (benign versus malignant), histological subtype,
and grade.
RESULTS
Of the 34 patients referred to our institution for surgical
management of their musculoskeletal chest wall tumors, a
total of 40 core needle biopsies and 35 tumor resections were
performed (Figure 1). Five patients had more than one core
needle biopsy before surgical resection, and one patient with
a recurrence underwent reresection. There were no reported
complications, including hemorrhage, pneumothorax, or neu-
rovascular injury, from the image-guided needle biopsies.
Patient Characteristics
Characteristics of the 34 patients that underwent surgi-
cal resection for chest wall tumors were evaluated (Table 1).
Seven had benign (21%) and 27 (79%) had malignant tumors.
There was even distribution by sex and wide range of ages;
half of the patients (50%) were men with an average age of 54
years (range: 22–90 years). The most common examination
finding was a palpable mass, and symptom was pain (Table 1).
n=40 CNB samples
[35 patients, 36 tumors]




































FIGURE 1. Core needle biopsy outcomes. aOne patient had
a complete response; therefore, no malignant cells were
present to classify bony versus soft tissue origin.
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Core Needle Biopsy Outcomes
The results of the 40 core needle biopsy samples were
analyzed (Figure 1). Ten samples were from benign and 30
were from malignant tumors. Most of the core needle biopsy
samples from malignant neoplasms were adequate (83%),
whereas in benign tumors, only 30% were adequate. The
majority of the nondiagnostic samples from benign lesions
were from bony tumors (80%), whereas the nondiagnostic
samples from sarcomas were from soft tissue tumors (100%;
Figure 1).
Soft Tissue versus Bony Sarcomas
Of the 35 tumors, 19 (54%) were soft tissue and 15
(43%) were bony in origin (Figure 1). One patient diagnosed
with treatment-related sarcoma (previously known as radia-
tion associated sarcoma) on core needle biopsy had complete
response to induction therapy and did not have any viable
malignant cells on the resection specimen for pathologic
comparison. There were six (86%) bony and one (14%) soft
tissue tumors in the benign group. Among the sarcomas, nine
(33%) were bony and 18 (67%) were soft tissue in origin
(Figure 1).
Detailed Tumor Characteristics
Tumor characteristics of the resected specimens are
described (Table 1). Twenty-eight (80%) of the chest wall
tumors were malignant, whereas seven (20%) were benign.
The average size was large in both benign (8.4 cm) and
malignant (10.2 cm) tumors. The majority of malignancies
were primary chest wall sarcomas (79%), whereas 14 and 7%
were metastatic or recurrent, respectively. Most of the chest
wall tumors required full thickness resection that included
ribs in benign (86%) and malignant (86%) groups. Seven
patients (25%) required partial or complete sternectomy for
resection, and only two (7%) required concomitant clavicle
resection.
The location of the tumors was widely distributed on
the chest wall: 10 (29%) were anterior, 11 (31%) were
posterior, and 10 (29%) were lateral. Four chest wall sarco-
mas arose in the sternum (14%). A vast array of different
histological subtypes of chest wall musculoskeletal tumors
was resected (Table 2).
Nondiagnostic Core Needle Biopsies
There were 12 nondiagnostic core needle biopsy out-
comes in eight patients. A detailed summary of the eight
resected tumors are described (Table 3). Forty-two percent
(5/12 biopsies) of nondiagnostic findings occurred due to
insufficient tissue obtained at biopsy. The remainder had
sufficient tissue, but the pathologist was unable to determine
a specific histologic diagnosis (Table 3). Most of the nondi-
agnostic biopsy specimens were from benign musculoskeletal
tumors. Five of the biopsies in the benign group occurred in
bony tumors, suggesting a possible technical difficulty in
needle penetration of the bony cortex. There was no identi-
fiable age or gender predilection. All the tumors were at least
5 cm in size, and only one did not require rib resection.
TABLE 1. Patient and Tumor Characteristics
Benign Malignant
Number of patients 7 27
Male 2 15
Female 5 12
Average age (yr) 50.4 55.1
Age range (yr) 22–81 28–90
Palpable mass 3 (43%) 13 (48%)
Pain symptoms 3 (43%) 10 (37%)
Number of resected tumors 7 28
Average size 8.4 cm 10.2 cm
Size range 4–15 cm 2–21 cm
Average volumea 254 cm3 524 cm3
Volume range 32–1200 cm3 11–2185 cm3
Low/intermediate gradeb NA 11/27 (41%)
High grade NA 16/27 (59%)
Primary 7/7 (100%) 22/28 (79%)
Recurrent NA 2/28 (7%)
Metastatic NA 4/28 (14%)
Ribs resected 6/7 (86%) 24/28 (86%)
Number of ribs resected 0–6 0–8
Average ribs resected 2.1 3.0
Clavicle resected 0/8 (0%) 2/28 (7%)
Sternum resected 0/8 (0%) 7/28 (25%)
a Three malignant tumor volumes were unknown.
b One patient had a complete response, and no tumor was seen on final pathology.
NA, not applicable.
TABLE 2. Final Histological Subtypes of Resected
Specimens
No. of Samples
Benign (n  7)
Periosteal chondroma 1
Chondroma 1
Polyostotic fibrous dysplasia 1










Sarcoma not otherwise specified 2
Dedifferentiated liposarcoma 2
Solitary fibrous tumor 1
Malignant granular cell tumor 1
Synovial versus MPNST 1
Myxoid liposarcoma 1
Myxofibrosarcoma 1
a One patient had complete response to neoadjuvant therapy.
PNET, primitive neuroectodermal tumor; MPNST, malignant peripheral nerve
sheath tumor.
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Accuracy of Core Needle Biopsy
Diagnostic accuracy of core needle biopsy was evalu-
ated in benign and malignant chest wall tumors (Table 4).
Overall, 28 of the 40 core needle biopsy samples (70%) were
adequate for histopathological diagnosis. The yield of core
needle biopsy was better for malignant sarcomas compared
with benign musculoskeletal tumors (Table 4). Of the ade-
quate samples, the accuracy of determining malignancy ver-
sus benign was 100%. Of the malignant sarcomas, the accu-
racy for histologic subtype and grade was 92 and 87%,
respectively. There was no difference in accuracy based on
the location of the tumor on the chest wall.
The adequate core needle biopsy samples were evalu-
ated for sensitivity and specificity (Table 5). With exclusion
of the nondiagnostic samples, the sensitivity and specificity
were both 100%. This demonstrates that a malignant diagno-
sis can be obtained confidently by core needle biopsy. The
malignant core needle biopsy samples were evaluated for
grade (Table 6). The sensitivity and specificity were 77 and
100%, respectively.
COMMENT
Chest wall musculoskeletal tumors are comprised of
many histological subtypes. Although certain bony sarcomas
such as osteosarcoma or primitive neuroectodermal tumors
(Ewing sarcoma) have accepted and established roles for
chemotherapy and radiation, the application of multimodality
approaches particularly in soft tissue sarcomas remains con-
troversial. Several reports have evaluated the use of neoad-
juvant regimens to guide treatment.10,11 The potential advan-
tages of preoperative therapy include (1) tumor reduction and
improved likelihood of complete (R0) resection, (2) immedi-
ate systemic therapy for micrometastatic disease, and (3)
pathologic evaluation of effectiveness of preoperative therapy
after surgical resection. Preoperative diagnosis of sarcoma
and grade are prerequisites to these investigational or insti-
tutional management approaches that apply neoadjuvant
treatment. Also, determination of a benign tumor can guide
the extent of surgical resection.
Given that chest wall sarcomas are rare mesenchymal
tumors, a multidisciplinary team approach to musculoskeletal
sarcomas has been advocated.5,7,9,12 In our review of the
literature, there is a paucity of articles that report the utiliza-
tion of core needle biopsy as a diagnostic method specifically
for chest wall sarcomas. Although there are numerous studies
that reported the experience of needle biopsies in chest wall
lesions, these studies focused mainly on epithelial malignan-
TABLE 3. Nondiagnostic Core Needle Biopsies
Diagnosis Age (yr) Sex Size (cm) No. of Ribs Grade No. of CNB Pathology Finding Outcome
Benign
Chondroma 78 M 6 2 NA 2 No. 1: Fibrofatty tissue, skeletal muscle Resection
No. 2: Low grade adipose tissue, fat necrosis
Periosteal chondroma 81 F 5.5 4 NA 2 No. 1: Hyaline cartilage Resection
No. 2: Insufficient tissue
Interosseous hemangioma 67 M 10 1 NA 1 Blood and inflammatory cells Resection
Fibrolipoma 36 F 5 0 NA 1 Insufficient tissue Resection
Giant cell tumor 31 F 13.5 1 NA 1 Giant cell rich lesion Resection
Malignant
Desmoid tumor 65 M 9.8 5 Low 3 No. 1: Unknown Resection
No. 2: Insufficient tissue
No. 3: Insufficient tissue
Dedifferentiated liposarcoma 81 M 10 6 High 1 Insufficient tissue Repeat CNB
Treatment-related sarcoma 38 F 8 1 High 1 Spindle cell proliferation Open biopsy
CNB, core needle biopsy; NA, not applicable.
TABLE 4. Overall Accuracy of Core Needle Biopsy
Benign Malignant
Adequacy (%) 30 83
Correct malignancy (%) NA 100
Correct grade (%) NA 87
Correct histology (%) 100 92
NA, not applicable.





Benign 3 0 3
Malignant 0 24a 24






a Two specimens were correct for malignancy but incorrect for final histology.
b Of the 28 adequate samples, one patient was excluded because of complete
response.
CNB, core needle biopsy; ND, nondiagnostic; PPV, positive predictive value; NPV,
negative predictive value.
Kachroo et al. Journal of Thoracic Oncology • Volume 7, Number 1, January 2012
Copyright © 2011 by the International Association for the Study of Lung Cancer154
cies (i.e., carcinomas) with limited inclusion of chest wall
sarcomas, and benign entities included not only tumors but
also infection (i.e., chest wall abscesses). As such, reports
that address the efficacy of core needle biopsies in chest wall
musculoskeletal tumors and specifically its effectiveness in
chest wall sarcomas are limited. Hau et al.6 reported that the
anatomical site has a significant effect on the accuracy of the
biopsy. Nevertheless, in most studies, the experience with
needle biopsy in the chest wall location was reported in the
data as part of other body sites. To our knowledge, only the
study from Walsh et al.9 reported their 10-year experience in
the management and treatment of chest wall sarcomas and
briefly described the use of fine needle aspiration or Tru-Cut
needle biopsy in 27 patients. Our study is unique in that it
specifically addresses the use of core needle biopsy in chest
wall sarcomas and focuses on the adequacy of tissue sample
obtained by needle biopsy and accuracy in determining ma-
lignancy, histological subtype, and high grade differentiation.
The importance of image guidance in needle biopsies
was demonstrated by Narvani et al.13 who reported that
biopsies obtained by image guidance are significantly more
accurate compared with blind biopsies (95% versus 78%).
Additionally, image guidance allows immediate evaluation
for procedure-related complications, such as hemorrhage or
pneumothorax. The reported incidence of needle biopsy-
related complications is 0 to 1.1%.12,14–16 In our series, all
core needle biopsies were performed with ultrasound or CT
guidance, and there were no procedure-related complications.
Although several reports have advocated needle tracts from
biopsies to be included within the field of surgical resection,
in our experience, unlike incisional or excisional surgical
biopsies, the use of core needle biopsy has eliminated the
need to include the biopsy site at the time of tumor resec-
tion.8,12,15,17 This practice has not resulted in chest wall
recurrences after core needle biopsies. Presumably, the use of
image guidance with an inner and outer core needle method
may prevent tracking of tumor along the needle trajectory.
Core needle biopsy has been shown to be an accurate
diagnostic modality for musculoskeletal tumors in various
body sites. Our series demonstrated a diagnostic adequacy of
core needle biopsy specifically in chest wall musculoskeletal
tumors to be 70%, which is comparable with the reported 79
to 100% in other body sites.13,18,19 Tumor characteristics may
impact the adequacy and diagnostic accuracy. In our series,
the majority of nondiagnostic samples from benign lesions
were from bony tumors (80%), whereas nondiagnostic ma-
lignant sarcomas were from soft tissue tumors (100%). Sev-
eral studies reported decreased diagnostic yield for bony
compared with soft tissue tumors, identifying cortex penetra-
tion as a possible hindrance to achieving adequate samples.5,6
Furthermore, cystic or vascular tumors may be more difficult
to obtain diagnostic tissue.7 The use of positron emission
tomography/CT may direct image-guided needle biopsy pro-
cedures to metabolically active areas with possibly higher
diagnostic accuracy.20 Additionally, several authors de-
scribed tumor heterogeneity including areas of tumor necro-
sis, fibrosis, or hemorrhage, as a factor that may contribute to
difficult diagnosis of soft tissue tumors.8,21,22
Our overall accuracy for determining a malignant sam-
ple was 100%, and the sensitivity and specificity of core
needle biopsy to diagnose chest wall sarcomas were both
100%. These results are comparable with reports for muscu-
loskeletal tumors in other body locations (sensitivity 82–
100% and specificity 94–100%).12,15,16,18,19,23–25 We reported
accuracies for correct histology and grade in chest wall
sarcomas to be 92 and 87%, respectively. Specifically, the
sensitivity and specificity of using core needle biopsy to
determine sarcoma grade in our study were 77 and 100%,
respectively. Several authors have also reported decreased
accuracy in identifying grade when compared with histolog-
ical subtypes, citing ranges for sensitivity and specificity of
81 to 89 and 95 to 100%, respectively.12,24 All our specimens
were reviewed by dedicated musculoskeletal pathologists.
The importance of specimen evaluation by an experienced
sarcoma pathologist is emphasized in other series.23
Given these findings, our report demonstrates that im-
age-guided core needle biopsy is a safe and highly accurate
diagnostic modality to determine malignancy, histological
subtype, and high grade differentiation of chest wall muscu-
loskeletal tumors. Core needle biopsy is an important com-
ponent in the multidisciplinary approach to the management
of chest wall sarcomas, especially when induction therapy is
considered and should ideally be used in the context of
experienced radiologists and musculoskeletal pathologists to
achieve highly accurate diagnostic results.
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